Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Part of paid clinical trials in Los Angeles, California.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT01084330
Phase
PHASE2
Status
Completed

Conditions

  • Advanced Gastric Cancer
  • Gastro-esophageal Junction Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AUY922 — DRUG
    70mg/m2
  • Docetaxel — DRUG
    Docetaxel 75mg/m2
  • Irinotecan — DRUG
    Iriniotecan 350mg/m2

Study Details

A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.

Key Dates

Start date
Apr 30, 2010
Status verified
Aug 2020
Primary completion
May 31, 2012
Completion
May 31, 2012

Study Design

Enrollment
68 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: AUY922
  • Active Comparator: Docetaxel or Irinotecan

Primary Outcome Measure

Progression Free Survival [ Time Frame: 21 day cycle: treatment until death, lost to follow up or withdrawal ]

Locations (7)

Find similar trials in Los Angeles, CA

Related Studies